

BME – GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 16th December 2022

COMMUNICATION – OTHER RELEVANT INFORMATION – FACEPHI BIOMETRIA S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the consolidated text of the Spanish Securities Market Law, approved by the Royal Legislative Decree 4/2015, of 23rd October, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter “Facephi” or “the Company”, interchangeably).

The Board of Directors of the Company, proceeded to ratify, pursuant the proposal of the Appointments and Remuneration Committee, the new composition of the Audit Committee and Appointments and Remuneration Committee, as follows:

COMISION DE AUDITORIA (Audit):

- Presidente: Pablo Reig Boronat
- Vocal: Fernando Orteso de Travesedo
- Secretario: Juan Alfonso Ortiz Company

COMISION DE NOMBRAMIENTOS Y RETRIBUCIONES (Appointments and remunerations):

- Presidente: Fernando Orteso de Travesedo
- Vocal: Pablo Reig Boronat
- Secretario: Juan Alfonso Ortiz Company

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors